A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
A cross-sectional study shows that type 2 diabetes and body mass index independently worsen arterial stiffness, with BMI having a greater impact. No synergy was found between the two risk factors.
Removing olfactory groove meningioma may improve blood sugar control in diabetes patients, a JAMA Network Open study finds. Both intermittent and continuous calorie restriction also improve metabolic health in type 2 diabetes.
Recent studies show that resistance training lowers cardiovascular disease risk in women, muscular strength is tied to lower mortality in older women, and both weekend warrior and regular exercise patterns reduce mortality in patients with hypertension.
Multiple new studies highlight key factors affecting children's health and development. Research shows maternal cardiovascular health during pregnancy significantly impacts child developmental delays, with poor heart health increasing risk by 62%. A separate study found family finances and neighborhood opportunities account for about 16% of variability in children's brain function, while parental concern about illness proved highly accurate for detecting serious conditions in children.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
A four-week dietary intervention reduced biological age in adults aged 65-75, with the strongest effect from an omnivorous high-carbohydrate diet. The Aging Cell study used 20 biomarkers. Longer-term research is needed.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
